Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 233 citing articles:

COVID-19 vaccine development: milestones, lessons and prospects
Maochen Li, Han Wang, Lili Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 331
Evaluation of the safety profile of COVID-19 vaccines: a rapid review
Qianhui Wu, Matthew Z. Dudley, Xinghui Chen, et al.
BMC Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 213
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Simon Galmiche, Liêm Binh Luong Nguyen, Éric Tartour, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 163-177
Open Access | Times Cited: 175
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
Shabir A. Madhi, Anthonet Koen, Alane Izu, et al.
The Lancet HIV (2021) Vol. 8, Iss. 9, pp. e568-e580
Open Access | Times Cited: 147
The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)
Bezawit A. Woldemeskel, Andrew H. Karaba, Caroline C. Garliss, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 7, pp. 1268-1270
Open Access | Times Cited: 136
Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count
Andrea Antinori, Stefania Cicalini, Silvia Meschi, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 1, pp. e552-e563
Open Access | Times Cited: 110
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
Alessandra Vergori, Alessandro Cozzi Lepri, Stefania Cicalini, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 87
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
Zabrina L. Brumme, Francis Mwimanzi, Hope R. Lapointe, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 84
Impaired antibody response to COVID-19 vaccination in advanced HIV infection
Nolan Hassold, Ségolène Brichler, Élise Ouédraogo, et al.
AIDS (2022) Vol. 36, Iss. 4, pp. F1-F5
Open Access | Times Cited: 75
Covid-19 vaccine immunogenicity in people living with HIV-1
Lauriane Nault, Lorie Marchitto, Guillaume Goyette, et al.
Vaccine (2022) Vol. 40, Iss. 26, pp. 3633-3637
Open Access | Times Cited: 68
Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
Thiago Cerqueira‐Silva, Vinícius de Araújo Oliveira, Viviane Boaventura, et al.
The Lancet Regional Health - Americas (2021) Vol. 6, pp. 100154-100154
Open Access | Times Cited: 86
Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination
Haya Altawalah
Vaccines (2021) Vol. 9, Iss. 8, pp. 910-910
Open Access | Times Cited: 69
COVID-19 Outcomes and Risk Factors Among People Living with HIV
Matthew A. Spinelli, Benjamin L. Jones, Monica Gandhi
Current HIV/AIDS Reports (2022) Vol. 19, Iss. 5, pp. 425-432
Open Access | Times Cited: 66
SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene
Hyunjhung Jhun, Ho‐Young Park, Yasmin Hisham, et al.
Immune Network (2021) Vol. 21, Iss. 5
Open Access | Times Cited: 61
Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study
Yanmeng Feng, Yifan Zhang, Zhangyufan He, et al.
EClinicalMedicine (2021) Vol. 43, pp. 101226-101226
Open Access | Times Cited: 61
Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients
Matthijs Oyaert, Marie‐Angélique De Scheerder, Sophie Van Herrewege, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 53
A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders
Farnoosh Seirafianpour, Homa Pourriyahi, Milad Gholizadeh Mesgarha, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 6
Open Access | Times Cited: 52
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
Shabir A. Madhi, Dhayendre Moodley, Sherika Hanley, et al.
The Lancet HIV (2022) Vol. 9, Iss. 5, pp. e309-e322
Open Access | Times Cited: 49
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
Lucas Chaves Netto, Karim Yaqub Ibrahim, Camila de Melo Picone, et al.
The Lancet HIV (2022) Vol. 9, Iss. 5, pp. e323-e331
Open Access | Times Cited: 48
Intention to Receive a COVID-19 Vaccine by HIV Status Among a Population-Based Sample of Women and Gender Diverse Individuals in British Columbia, Canada
Angela Kaida, Lori A. Brotto, Melanie Murray, et al.
AIDS and Behavior (2022) Vol. 26, Iss. 7, pp. 2242-2255
Open Access | Times Cited: 47
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
Ling Ao, Ting Lu, Yu Cao, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1126-1134
Open Access | Times Cited: 45
Duration of immunity following full vaccination against SARS-CoV-2: a systematic review
Isaac Yeboah Addo, Frederick Dadzie, Sylvester Reuben Okeke, et al.
Archives of Public Health (2022) Vol. 80, Iss. 1
Open Access | Times Cited: 45
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Lynda Coughlan, Eric J. Kremer, Dmitry M. Shayakhmetov
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1822-1849
Open Access | Times Cited: 44
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study
Kathryn S. Hensley, Marlou J. Jongkees, Daryl Geers, et al.
PLoS Medicine (2022) Vol. 19, Iss. 10, pp. e1003979-e1003979
Open Access | Times Cited: 39
Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China
Xiaojie Huang, Ying Yan, Bin Su, et al.
Viruses (2022) Vol. 14, Iss. 2, pp. 277-277
Open Access | Times Cited: 38
Page 1 - Next Page

Scroll to top